Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro Tablets, QD, Compared to Prograf Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant

Trial Profile

Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro Tablets, QD, Compared to Prograf Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Veloxis Pharmaceuticals
  • Most Recent Events

    • 19 Dec 2018 According to a Veloxis Pharmaceuticals media release, based on the data from this trial of the phase 3 clinical development program, the U.S. FDA has approved a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection in de novo kidney transplant patients in combination with other immunosuppressants.
    • 19 Apr 2018 According to Veloxis Pharmaceuticals media release, the Food & Drug Administration (FDA) has accepted for standard review the Company's supplemental New Drug Application (sNDA) for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants. The FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of January 7, 2019.
    • 07 Mar 2018 According to Veloxis Pharmaceuticals media release company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants. The sNDA is based on data from this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top